Fibroblast growth factor 23 (FGF23)
Homo sapiens — UniProt Q9GZV9
Data last refreshed: (UniProt release unknown)
Key facts
Fibroblast growth factor 23 (FGF23) is a protein from Homo sapiens identified by UniProt accession Q9GZV9, 251 residues long. MolForge cross-references it against 1 known binders and 756 disease associations.
- UniProt accession: Q9GZV9; gene symbol FGF23.
- Organism: Homo sapiens.
- Length: 251 amino acids.
- Approved drugs acting on it (DrugCentral): Burosumab.
- Top disease associations (Open Targets): autosomal dominant hypophosphatemic rickets, tumoral calcinosis, hyperphosphatemic, familial, 2 and familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Fibroblast growth factor 23 |
|---|---|
| UniProt accession | Q9GZV9 |
| Gene | FGF23 |
| Organism | Homo sapiens |
| Length | 251 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (1)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (756)
Diseases linked to this target (Open Targets).
- autosomal dominant hypophosphatemic rickets · score 0.74
- tumoral calcinosis, hyperphosphatemic, familial, 2 · score 0.73
- familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome · score 0.63
- cancer · score 0.61
- bone development disease · score 0.60
- X-linked hypophosphatemia · score 0.58
- Hypophosphatemia · score 0.54
- osteomalacia · score 0.52
- hypophosphatemic rickets · score 0.41
- epidermal nevus syndrome · score 0.39
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9GZV9-F1 | alphafold | PREDICTED | 76.64 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9GZV9.
Amino-acid sequence (251 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target FGF23?
DrugCentral lists 1 approved drug whose mechanism of action is FGF23: Burosumab.
Which diseases are associated with FGF23?
The strongest Open Targets associations for FGF23 are autosomal dominant hypophosphatemic rickets, tumoral calcinosis, hyperphosphatemic, familial, 2, familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome, cancer and bone development disease.
How long is the FGF23 protein?
The Homo sapiens FGF23 protein (UniProt Q9GZV9) is 251 amino acids long.
Browse: Targets: F · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9GZV9 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9GZV9 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.